Additionally, increased exposure to lenvatinib is correlated with an increased incidence and severity of treatment-emergent hypertension [57], which is a demonstrated class effect of agents targeting the VEGF/VEGFR signaling pathway [58]. Here, VEGFA is linked to Hypertension.